Acrux gets go-ahead for Phase III
Wednesday, 25 June, 2008
The US FDA has granted Acrux (ASX: ACR) approval to commence Phase III clinical trials of its Testostorone MD-Lotion.
The open-label trial will involve up to 150 hypogonadal men, who will take the recommended dosage for a period of four months.
Thanks to the approval, Acrux remains on target to launch the product in the fourth quarter of 2009, the company said.
Acrux said the product had several distinct advantages over current leading testosterone treatments.
It is a quick-drying solution that is applied to the armpits via a no-touch applicator, compared to the current treatments of a slow-drying gel which must be rubbed into the shoulders, upper torso or arms.
Low testosterone sufferers undergoing current treatments run the risk of transferring the drug to others due to treatment residue remaining on the hands.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
